Synthetic Biologics Inc (SYN) |
|
0.85 -0.073 (-7.92%)
|
01-27 05:28 |
|
Open: |
0.9172 |
Pre. Close: |
0.9231 |
|
High:
|
0.92 |
Low:
|
0.8369 |
|
Volume:
|
12,590,599 |
Market Cap:
|
46M |
|
|
|
|
Synthetic Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. The company is headquartered in Rockville, Maryland and currently employs 13 full-time employees. The firm is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The firm's lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection (CDI) and antibiotic-associated diarrhea (AAD). Its other product candidates include SYN-007, SYN-006, SYN-005, SYN-200 and SYN-020. The firm is also developing preclinical-stage monoclonal antibody therapies for the prevention and treatment of pertussis, and discovery-stage biotherapeutics for the treatment of phenylketonuria (PKU). |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.921 - 0.925 |
0.925 - 0.929 |
|
Low:
|
0.83 - 0.834 |
0.834 - 0.838 |
|
Close:
|
0.843 - 0.85 |
0.85 - 0.856 |
|
Technical analysis |
as of: 2021-01-26 4:49:20 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 1.37 One year: 1.99 |
| Support: |
Support1: 0.32 Support2: 0.27 |
| Resistance: |
Resistance1: 1.17 Resistance2: 1.70 |
| Pivot: |
0.81  |
| Moving Average: |
MA(5): 0.87 MA(20): 0.71
MA(100): 0.45 MA(250): 0.45 |
| MACD: |
MACD(12,26): 0.12 Signal(9): 0.11 |
| Stochastic oscillator: |
%K(14,3): 34.75 %D(3): 37.17 |
| RSI: |
RSI(14): 60.59 |
| 52-week: |
High: 1.70 Low: 0.25 Change(%): 57.4 |
| Average Vol(K): |
3-Month: 1200913 10-Days: 2085767 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and BULLISH in mid-long term.SYN has closed below upper band by 41.1%. Bollinger Bands are 96% wider than normal. The large width of the bands suggest high volatility as compared to SYN's normal range. The bands have been in this wide range for 14 bars. This is a sign that the current trend might continue. |
|
|
Headline News |
Mon, 18 Jan 2021
Synthetic Biologics Inc. (SYN) Soars 8.15% on January 18 - Equities.com
Wed, 13 Jan 2021
Synthetic Biologics Inc. (SYN) Plunges 12.01% on January 13 - Equities.com
Wed, 06 Jan 2021
Synthetic Biologics Inc. (SYN) Plunges 16% on January 06 - Equities.com
Tue, 05 Jan 2021
Stocks That Hit 52-Week Highs On Tuesday - Benzinga
Tue, 05 Jan 2021
Pre-market Movers In Healthcare Sector: CHEK, SYN, NSPR, ZOM, BNGO, VRAY... - Nasdaq
Tue, 05 Jan 2021
Synthetic Biologics, Check-Cap leads healthcare gainers; Bionano Genomics, Mersana Therapeutics among major losers - Seeking Alpha
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
 |
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
n/a |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Underperform |
Price to Earnings: |
Underperform |
| Return on Equity: |
Underperform |
Debt to Equity: |
Neutral |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: AMEX |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
19 |
| Shares Float (M) |
19 |
|
% Held by Insiders
|
0.13 |
|
% Held by Institutions
|
8.72 |
|
Shares Short (K)
|
61 |
|
Shares Short P. Month (K)
|
206 |
Stock Financials |
|
EPS
|
-0.877 |
|
EPS Est This Year
|
-0.170 |
|
EPS Est Next Year
|
-0.250 |
|
Book Value (p.s.)
|
-0.400 |
|
Profit Margin
|
|
|
Operating Margin
|
|
|
Return on Assets (ttm)
|
-53.5 |
|
Return on Equity (ttm)
|
-111.5 |
|
Qtrly Rev. Growth
|
|
|
Gross Profit (p.s.)
|
|
|
Sales Per Share
|
|
|
EBITDA (p.s.)
|
-0.727 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-14 |
|
Levered Free Cash Flow (M)
|
-8 |
Stock Valuations |
|
PE Ratio
|
-0.97 |
|
PEG Ratio
|
|
|
Price to Book value
|
-2.13 |
|
Price to Sales
|
|
|
Price to Cash Flow
|
-1.21 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
